FDA.reportPublic FDA data

Myfembree (relugolix 40 MG / estradiol 1 MG / norethindrone acetate 0.5 MG) Oral Tablet

RxCUI
2556800
RxNorm name
Myfembree (relugolix 40 MG / estradiol 1 MG / norethindrone acetate 0.5 MG) Oral Tablet
Display name
Myfembree (relugolix 40 MG / estradiol 1 MG / norethindrone acetate 0.5 MG) Oral Tablet
Full name
Myfembree (relugolix 40 MG / estradiol 1 MG / norethindrone acetate 0.5 MG) Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:29

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
fc3feb73-cc84-43a8-aa32-b262460495e8Myfembree (relugolix 40 MG / estradiol 1 MG / norethindrone acetate 0.5 MG) Oral Tablet [PSN] · estradiol 1 MG / norethindrone acetate 0.5 MG / relugolix 40 MG Oral Tablet [Myfembree] [SBD] · Myfembree (relugolix 40 MG / estradiol 1 MG / norethindrone acetate 0.5 MG) Oral Tablet [SY]318These highlights do not include all the information needed to use MYFEMBREE safely and effectively. See full prescribing information for MYFEMBREE. MYFEMBREE ® (relugolix, estradiol, and norethindrone acetate) tablets, for oral use Initial U.S. Approval: 202120250904